Bio-Gene Technology Limited (ASX:BGT)
0.0200
0.00 (0.00%)
Jun 19, 2026, 4:10 PM AEST
Bio-Gene Technology Market Cap
Bio-Gene Technology has a market cap or net worth of 6.1 million as of June 18, 2026. Its market cap has decreased by -10.88% in one year.
Market Cap
6.10M
Enterprise Value
5.02M
Revenue
n/a
Ranking
n/a
PE Ratio
n/a
Stock Price
0.02
Market Cap Chart
Since November 29, 2017, Bio-Gene Technology's market cap has decreased from 20.89M to 6.10M, a decrease of -70.80%. That is a compound annual growth rate of -13.39%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jun 19, 2026 | 6.10M | -13.04% |
| Dec 29, 2025 | 7.02M | -18.97% |
| Dec 30, 2024 | 8.66M | -28.33% |
| Dec 29, 2023 | 12.08M | -32.09% |
| Dec 29, 2022 | 17.79M | -48.81% |
| Dec 31, 2021 | 34.76M | 61.59% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Nov 29, 2017 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Immuron | 9.80M |
| Invex Therapeutics | 9.77M |
| Vectus Biosystems | 9.22M |
| AdAlta | 7.97M |
| Acrux | 7.70M |
| Biotron | 6.75M |
| Tissue Repair | 6.05M |
| Zelira Therapeutics | 5.95M |